

CITATION REPORT

List of articles citing

Lean body mass as a predictor of drug dosage.
Implications for drug therapy

DOI: 10.2165/00003088-199426040-00005
Clinical Pharmacokinetics, 1994, 26, 292-307.

Source: <https://exaly.com/paper-pdf/25434546/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
231	Pharmacokinetics of midazolam in Vietnamese subjects. 1996 , 11, 1177-80		6
230	Application of population pharmacokinetics to the optimization of theophylline therapy. 1996 , 21, 113-25		17
229	Hepatic drug clearance in patients with mild cystic fibrosis. 1996 , 59, 529-40		16
228	Estimation of Background Exposure to Toluene Using a Physiologically-Based Kinetic Model. 1997 , 39, 130-137		2
227	Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. 1997 , 14, 309-15		17
226	Doseren op vetvrij lichaamsgewicht. 1997 , 35, 220-220		
225	Accuracy of a recently proposed method for estimating creatinine clearance in elderly debilitated patients. 1997 , 25, 227-36		
224	Relationships among liver and kidney volumes, lean body mass and drug clearance. 1998 , 46, 447-52		46
223	Drug disposition in cystic fibrosis. <i>Clinical Pharmacokinetics</i> , 1998 , 35, 313-29	6.2	128
222	Postpartum Patients Have Slightly Prolonged Neuromuscular Block After Mivacurium. 1998 , 86, 82-85		4
221	Postpartum patients have slightly prolonged neuromuscular block after mivacurium. 1998 , 86, 82-5		10
220	The obese patient in the ICU. 1998 , 113, 492-8		657
219	Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. 1999 , 213, 521-5		200
218	Individual Prior Information in a Physiological Model of 2H8-Toluene Kinetics: An Empirical Bayes Estimation Strategy. 1999 , 19, 1127-1134		4
217	Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. 1999 , 21, 227-32		4
216	Effects of gender and race on albuterol pharmacokinetics. 1999 , 19, 157-61		13
215	Pharmacokinetics of ibuprofen in patients with cystic fibrosis. 1999 , 19, 340-5		13

214	The accuracy of the estimation of body weight and height in the intensive care unit. 2000 , 17, 698-703		27
213	[Antibiotic therapy in cystic fibrosis. I. Pharmacologic specifics of antibiotics]. 2000 , 7, 519-28		4
212	Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. 2000 , 23, 255-78		26
211	Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 415-26	6.2	90
210	Effects of obesity on pharmacokinetics implications for drug therapy. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 215-31	6.2	437
209	Disproportionate alterations in body composition of large for gestational age neonates. 2001 , 138, 817-21		44
208	Commonly Used Equations for Estimating Lean Body Weight are Inaccurate. 2001 , 36, 955-961		
207	Prevalence and Predictive Value of Overweight in an Urban HIV Care Clinic. 2001 , 26, 291-297		45
206	Prevalence and predictive value of overweight in an urban HIV care clinic. 2001 , 26, 291-7		29
205	Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. 2001 , 7, 133-9		92
204	Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. 2001 , 9, 535-43		36
203	Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. 2001 , 86, 5830-7		164
202	Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection. 2001 , 45, 758-63		13
201	Considerations of anthropometric, tissue volume, and tissue mass scaling for improved patient specificity of skeletal S values. 2002 , 29, 1054-70		11
200	Prolonged neuromuscular block after rocuronium in postpartum patients. 2002 , 94, 686-9; table of contents		9
199	Body weight and response to vitamin K administration. 2002 , 112, 158-60		0
198	Dosing strategies for anticancer drugs: the good, the bad and body-surface area. 2002 , 38, 1677-84		141
197	Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. 2002 , 20, 81-7		84

196	Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. 2002 , 3, 9-15	155
195	Lean body mass-based standardized uptake value, derived from a predictive equation, might be misleading in PET studies. 2003 , 30, 473-4	1
194	Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. 2003 , 43, 1124-35	11
193	What is the best size descriptor to use for pharmacokinetic studies in the obese?. 2004 , 58, 119-33	261
192	Apport du dosage plasmatique des aminoglycosides. 2004 , 2004, 27-34	
191	Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. 2004 , 40, 1170-8	57
190	Resuscitation of the morbidly obese patient. 2004 , 22, 40-7	29
189	Can body volume be determined by PET?. 2005 , 32, 564-8	6
188	A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention. 2005 , 32, 1269-75	56
187	Quantification of lean bodyweight. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1051-65	6.2 577
186	Standardization of p-creatinine assays and use of lean body mass allow improved prediction of calculated glomerular filtration rate in adults: a new equation. 2006 , 66, 451-68	25
185	Critical care of the bariatric patient. 2006 , 34, 1796-804	98
184	Accuracy of weight and height estimation in an intensive care unit: Implications for clinical practice and research. 2006 , 34, 2153-7	105
183	Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. 2006 , 24, 367-75	18
182	Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-D: -glucose Injection following I.V. Insulin in diabetic patients. 2006 , 8, 348-54	38
181	Prediction of relative glomerular filtration rate in adults: new improved equations based on Swedish Caucasians and standardized plasma-creatinine assays. 2007 , 67, 678-95	63
180	Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. 2007 , 51, 2497-507	96
179	Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. 2007 , 13, 3264-8	380

178	Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. 2007 , 25, 4707-13	123
177	Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. 2007 , 21, 821-46, x	19
176	Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. 2007 , 19, 23-37	42
175	The Use of the Broselow Tape in Pediatric Resuscitation. 2007 , 14, 500-501	16
174	The dilemma of paediatric drug dosing and equipment sizing in the era of patient safety. 2007 , 19, 490-3	5
173	Severe paroxysmal hypertension (pseudopheochromocytoma). 2008 , 10, 12-8	29
172	The Lund-Malmström creatinine-based glomerular filtration rate prediction equation for adults also performs well in children. 2008 , 68, 568-76	32
171	Gender and body size affect the response of erythrocyte folate to folic acid treatment. 2008 , 138, 1456-61	19
170	Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography. 2008 , 29, 614-22	28
169	Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. 2009 , 15, 2920-6	694
168	Women need more propofol than men during EEG-monitored total intravenous anaesthesia / Frauen benötigen mehr Propofol als Männer während EEG-überwachter total-intravenöser Anästhesie. 2009 , 54, 76-82	11
167	Aggregate predictions improve accuracy when calculating metabolic variables used to guide treatment. 2009 , 89, 491-9	31
166	Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. 2009 , 125, 426-31	29
165	Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. 2009 , 65, 130-41	16
164	Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. 2009 , 50, 482-91	20
163	Drug disposition in obesity and protein-energy malnutrition. 2010 , 69, 543-50	25
162	Estimation of lean body weight in older community-dwelling men. 2010 , 69, 118-27	16
161	Accuracy of weight and height estimation in an intensive care unit. 2010 , 38, 930-4	37

160	Dose adjustment of anaesthetics in the morbidly obese. 2010 , 105 Suppl 1, i16-23	272
159	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. 2010 , 54, 1275-82	40
158	Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. 2010 , 48 Suppl 1, S52-9	32
157	Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. 2010 , 14, R53	139
156	The effects of obesity on drug pharmacokinetics in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 697-706	5.5 67
155	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. 2011 , 2, 27-39	6
154	Patient variation in veterinary medicine--part II--influence of physiological variables. 2011 , 34, 209-23	20
153	Minimierung kontrastmittelinduzierter Nephropathien. 2011 , 16, 469-480	6
152	An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. 2011 , 67, 93-101	103
151	The CKD-EPI and MDRD equations to estimate GFR. Validation in the Swedish Lund-Malmö Study cohort. 2011 , 71, 129-38	39
150	Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method. 2011 , 52, 634-41	6
149	Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. 2011 , 4, 238-43	25
148	Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. 2011 , 71, 232-9	117
147	The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. 2012 , 17, 1240-5	104
146	Population pharmacokinetics of single-dose intravenous paracetamol in children. 2012 , 108, 823-9	20
145	Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. 2012 , 34, 381-9	35
144	Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. 2012 , 56, 3232-8	70
143	Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures. 2012 , 53, 601-6	16

142	Comparison of SUVs Normalized by Lean Body Mass Determined by CT with Those Normalized by Lean Body Mass Estimated by Predictive Equations in Normal Tissues. 2012 , 46, 182-8	12
141	Importance of lean body mass in the oncologic patient. 2012 , 27, 593-8	60
140	Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. 2012 , 53, 872-80	77
139	Underdosing of common antibiotics for obese patients in the ED. 2012 , 30, 1212-4	28
138	Clinical nutrition, body composition and oncology: a critical literature review of the synergies. 2012 , 84, 37-46	31
137	Population-based input function and image-derived input function for [¹¹ C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. 2012 , 63, 1532-41	37
136	Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. 2012 , 31, 157-62	14
135	Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. 2012 , 6, 398-406	167
134	Estimation of lean body weight in older women with hip fracture. 2012 , 16, 188-92	7
133	Direct Determination of Lean Body Mass by CT in F-18 FDG PET/CT Studies: Comparison with Estimates Using Predictive Equations. 2013 , 47, 98-103	11
132	Effects of chemical immobilization on the movement rates of free-ranging polar bears. 2013 , 94, 386-397	19
131	[Total intravenous anaesthesia in geriatrics: the example of propofol]. 2013 , 60, 327-35	7
130	Discrepancy between body surface area and body composition in cancer. 2013 , 65, 1151-6	6
129	Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. 2013 , 76, 897-907	27
128	Sex differences in the drug therapy for oncologic diseases. 2012 , 411-42	48
127	Appendicitis in obese children. 2013 , 29, 537-44	16
126	Diagnostic measures for sarcopenia and bone mineral density. 2013 , 24, 2681-91	47
125	Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. 2013 , 35, 871-81	160

124	Body composition in chemotherapy: the promising role of CT scans. 2013 , 16, 525-33	44
123	Pharmacokinetics of Antimicrobials in Obese Children. 2013 , 2, 76-81	12
122	Pharmacokinetics of drugs in cachectic patients: a systematic review. 2013 , 8, e79603	60
121	The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. 2014 , 39, 693-8	37
120	A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. 2014 , 24, 1759-64	25
119	A fixed-dose ketamine protocol for adolescent sedations in a pediatric emergency department. 2014 , 165, 453-8	9
118	Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with ¹⁵³ Sm-EDTMP. 2014 , 41, 238-52	23
117	Low skeletal muscle is associated with toxicity in patients included in phase I trials. 2014 , 32, 382-7	47
116	The predictors of cholelithiasis in female patients with metabolic syndrome. 2014 , 9, 108-114	1
115	Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 479-88	6.2 24
114	Correlation of abdominal fat ratio with hepatic CT enhancement. 2015 , 10, 285-288	0
113	Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer. 2015 , 22, 2560-6	68
112	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. 2015 , 33, 257-68	40
111	Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. 2015 , 90, 85-91	55
110	A Review of the Toxicologic Implications of Obesity. 2015 , 11, 342-54	18
109	Need for gender-specific pre-analytical testing: the dark side of the moon in laboratory testing. 2015 , 179, 514-35	19
108	Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections. 2016 , 48, 209-215	5
107	Effect of Acetaminophen Ingestion on Thermoregulation of Normothermic, Non-febrile Humans. 2016 , 7, 54	15

106	Prediction of Fat-Free Mass in Kidney Transplant Recipients. 2016 , 38, 439-46	3
105	Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. 2016 , 13, e39-e45	47
104	Levothyroxine Dosing Following Bariatric Surgery. 2016 , 26, 2538-42	20
103	The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. 2016 , 21, 1396-1409	104
102	Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. 2016 , 5, 607-16	87
101	Review of commonly used age-based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs. 2016 , 81, 849-56	12
100	First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. 2016 , 57, 1858-1864	91
99	Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. 2016 , 75, 199-211	240
98	Usefulness of standardized uptake value normalized by individual CT-based lean body mass in application of PET response criteria in solid tumors (PERCIST). 2016 , 9, 170-7	3
97	Sex and race differences in QRS duration. 2016 , 18, 1842-1849	27
96	[Impact of cancer muscle mass loss on anticancer treatment toxicities]. 2016 , 103, 786-93	2
95	Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. 2016 , 72, 813-22	13
94	The Optimal Body Size Index with Which to Determine Iodine Dose for Hepatic Dynamic CT: A Prospective Multicenter Study. 2016 , 278, 773-81	48
93	Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. 2017 , 40, 47-52	63
92	Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. 2017 , 61,	6
91	Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. 2017 , 79, 587-594	2
90	Optimal propofol induction dose in morbidly obese patients: A randomized controlled trial comparing the bispectral index and lean body weight scalar. 2017 , 64, 471-479	16
89	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. 2017 , 83, 1688-1700	6

88	Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types. 2017 , 57, 977-987		13
87	Sarcopenia in gastric cancer: when the loss costs too much. 2017 , 20, 563-572		33
86	Performing nuclear medicine examinations in pregnant women. 2017 , 43, 159-164		10
85	Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapiomod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. 2017 , 17, 145-158		2
84	What is the best size predictor for dose in the obese child?. 2017 , 27, 1176-1184		36
83	Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. 2017 , 123, 4868-4877		49
82	Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies. 2017 , 64, 1417-1438		11
81	Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. 2017 , 18, e129-e136		34
80	The Accuracy of a Patient's Weight Estimated by Their Relatives, Is It Gender Dependent?. 2017 , 37, 717-723		
79	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. 2018 , 95, 1-7		5
78	Determinants of amikacin first peak concentration in critically ill patients. 2018 , 32, 669-677		5
77	Sedation of the Obese Patient: Indications, Management, and Complications. 2018 , 123-138		
76	A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 781-795	6.2	9
75	Abdominal CT: a radiologist-driven adjustment of the dose of iodinated contrast agent approaches a calculation per lean body weight. 2018 , 2, 41		16
74	Show me your face and I will tell you your height, weight and body mass index. 2018 ,		16
73	Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients. 2018 , 18, 955		14
72	Beta -adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. 2018 , 596, 4121-4139		23
71	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. 2018 , 123, 416-428		3

70	Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study. 2018 , 9, 37		2
69	Early breast cancer: why does obesity affect prognosis?. 2018 , 77, 369-381		10
68	F-FDG PET/CT as a prognostic factor in penile cancer. 2019 , 46, 855-863		9
67	Establishment of Prediction Equations of Lean Body Mass Suitable for Chinese Adults. 2019 , 2019, 1757954		1
66	Muscle derangement and alteration of the nutritional machinery in NSCLC. 2019 , 141, 43-53		10
65	Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. 2019 , 33, 381-389		2
64	Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review. 2019 , 51, 1-11		2
63	Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers. 2020 , 50, 288-296		1
62	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. 2020 , 61, 512-519		86
61	Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 475-483	6.2	3
60	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. 2020 , 22, 223		5
59	Uterine Exteriorization Compared With In Situ Repair of Hysterotomy After Cesarean Delivery: A Randomized Controlled Trial. 2020 , 135, 1145-1151		8
58	Modern pharmacological treatment of obese patients. 2020 , 11, 2042018819897527		28
57	Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. 2020 , 25, 161-169		10
56	Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 447-470	6.2	0
55	A method for evaluation of patient-specific lean body mass from limited-coverage CT images and its application in PERCIST: comparison with predictive equation. 2021 , 8, 12		0
54	Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy. 2021 , 28, 1325-1337		4
53	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). 2021 , 147, 128-139		0

52	Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study. 2021 , 14, 2008-2016	1
51	Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. 2021 , 46, 479-485	1
50	Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. 2021 , 48, 3666-3682	2
49	Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?. 2021 , 33, e540-e552	3
48	Ultrasound evaluation of inferior vena cava compression in tilted and supine term parturients. 2021 , 68, 1507-1513	3
47	Contrast media dose adjustment to allometric parameters of body mass in multiphasic CT of the liver: A comparison of different metrics. 2021 , 141, 109778	
46	Diagnostic and prognostic values of 2-[F]FDG PET/CT in resectable thymic epithelial tumour. 2021 , 1	1
45	Appropriate dose of levothyroxine replacement therapy for hypothyroid obese patients. 2021 , 25, 100264	0
44	Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. 2020 , 261, 231-255	1
43	The Uses and Misuses of Body Surface Area in Medicine. 2012 , 307-320	2
42	Applied Pharmacometrics in the Obese Population. 2014 , 161-187	3
41	Influence of Overweight and Obesity on Medication. 2009 , 167-205	1
40	A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. 1996 , 24, 1473-81	62
39	The accuracy of the estimation of body weight and height in the intensive care unit. 2000 , 17, 698-703	45
38	Standard peritoneal permeability analysis in children. 2000 , 11, 943-950	29
37	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. 2021 , 46, 807-816	1
36	Allgemeine Pharmakologie. <i>Springer-Lehrbuch</i> , 2002 , 1-73	0.4
35	Pharmacokinetics. 2003 , 805-820	

34	Defining the Starting Dose. 2004 , 57-73		3
33	REFLUX IN THE MORBIDLY OBESE. 2008 , 239-244		
32	Factors Influencing Peripheral Conversion of Thyroxine to Tri-Iodothyronine in Athyreotic Individuals during Levothyroxine Replacement. 2010 , 25, 119		
31	Postoperative Care After Bariatric Surgery. 2010 , 577-589		3
30	Defining the Starting Dose: Should It Be mg/kg, mg/m ² , or Fixed?. <i>Cancer Drug Discovery and Development</i> , 2014 , 69-87	0.3	
29	Allgemeine Pharmakologie. <i>Springer-Lehrbuch</i> , 1997 , 1-71	0.4	
28	Basic elements of applied pharmacology in the intensive care unit. 1998 , 111-123		
27	Allgemeine Pharmakologie. <i>Springer-Lehrbuch</i> , 1999 , 1-71	0.4	
26	Postoperative Care After Bariatric Surgery. 2016 , 679-691		
25	Lean body weight versus total body weight to calculate the iodinated contrast media volume in abdominal CT: a randomised controlled trial. <i>Insights Into Imaging</i> , 2020 , 11, 132	5.6	1
24	Obesity-associated changes in drug pharmacokinetics. <i>Vnitřni Lekarství</i> , 2020 , 66, 465-471	0.3	1
23	Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?. <i>Journal of Extra-Corporeal Technology</i> , 2005 , 37, 153-6	0.4	3
22	Malnutrition, maintenance dose intensity and event-free survival in children with acute lymphoblastic leukemia. 2002 , 4, 308-313		1
21	Current status and future outlooks on therapeutic drug monitoring of fluorouracil.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	1
20	Comparison of ten predictive equations for estimating lean body mass with dual-energy X-ray absorptiometry in older patients.. <i>British Journal of Radiology</i> , 2022 , 20210378	3.4	0
19	Effect of Acetaminophen on Endurance Cycling Performance in Trained Triathletes in Hot and Humid Conditions.. <i>International Journal of Sports Physiology and Performance</i> , 2022 , 1-9	3.5	
18	Body composition and chemotherapy toxicity in women with early breast cancer (CANDO-3): protocol for an observational cohort study.. <i>BMJ Open</i> , 2022 , 12, e054412	3	1
17	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. <i>Wellcome Open Research</i> , 7, 72	4.8	

16	Official position of the Brazilian Association of Bone Assessment and Metabolism (ABRASSO) on the evaluation of body composition by densitometry: part I (technical aspects)-general concepts, indications, acquisition, and analysis.. <i>Advances in Rheumatology</i> , 2022 , 62, 7	3	0
15	Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 ,	10.3	1
14	Lean body mass and total body weight versus body surface area as a determinant of docetaxel pharmacokinetics and toxicity. 2022 , Publish Ahead of Print,		
13	Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil.		
12	Isoniazid preventive therapy-related adverse events among Malawian adults on antiretroviral therapy: A cohort study. 2022 , 101, e30591		0
11	Models for Drug Individualization: Patient to Population Level. 2022 , 303-322		0
10	Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes. 1-18		0
9	Lean body mass and the cardiovascular system constitute a female-specific relationship. 2022 , 14,		1
8	Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review. 12,		0
7	The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma. 2022 , 22,		0
6	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. 7, 72		0
5	Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors. 14,		0
4	Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD. 2023 , 12, 1642		1
3	Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia. 2023 , 188, 322-330		0
2	Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats.		0
1	Perioperative Acetaminophen Dosing in Obese Children. 2023 , 10, 625		0